Pharmacokinetics of Dasatinib
نویسندگان
چکیده
منابع مشابه
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
BACKGROUND The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating dasatinib, which could expand under selective pressures during treatment. However, it is also possible that Ph + ALL patients newly acquire the T315I mutation during dasatinib thera...
متن کاملDasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
PURPOSE Chronic myeloid leukemia (CML) is caused by reciprocal translocation between chromosomes 9 and 22, forming BCR-ABL, a constitutively activated tyrosine kinase. Imatinib mesylate, a selective inhibitor of BCR-ABL, represents current frontline therapy for CML; however, emerging evidence suggests that drug resistance to imatinib may limit its long-term success. To improve treatment options...
متن کاملComputational Study of Anticancer Dasatinib for Drug Delivery Systems
Dasatinib is a tyrosine kinase inhibitor (TKI) that is used to treat chronic myeloid leukemiaand in the management of ulcerative colitis (UC) and to provide appropriate results in treatment. Dasatinib is significantly higher and faster than full cytogenetic and large molecular responses as compared to imatinib. In the recent study, using the NMR data, thermochemical properties of the dasa...
متن کاملComputational study of Anticancer Dasatinib for drug delivery systems
Dasatinib is a tyrosine kinase inhibitor (TKI) that is used to treat chronic myeloid leukemia and in the management of ulcerative colitis (UC) and to provide appropriate results in treatment. Dasatinib is significantly higher and faster than full cytogenetic and large molecular responses as compared to imatinib. In the recent study, using the NMR data, the frequency and thermochemical propertie...
متن کاملThe shady side of dasatinib.
In this issue of Blood, Futosi and colleagues investigate the effects of the multikinase inhibitor dasatinib on mature human neutrophils, helping to explain the increased infection rate in chronic myelogenous leukemia (CML) patients resistant to or intolerant of imatinib. Through careful analysis of neutrophil function, the authors also develop a pathway for the development of kinase inhibitors...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prague Medical Report
سال: 2019
ISSN: 1214-6994,2336-2936
DOI: 10.14712/23362936.2019.10